Matthew Rabinowitz, Ph.D., is co-founder of Natera and currently serves as the executive chairman of its board of directors. From 2005-2009, he served as Natera’s chief executive officer.
Rabinowitz serves as a chairman, director and/or advisor to many companies and nonprofits involved in diagnostics, biotech, artificial intelligence (AI), health services, and nature conservation. Additionally, he manages an early stage technology venture fund focused on biotech, security, and AI.
Companies Rabinowitz has founded have twice received the World Economic Forum Technology Pioneer award and thrice received Edison Awards in the United States. He has served as consulting professor in Aeronautics and Astronautics at Stanford, as visiting faculty in Genetics at Harvard, and has received the Scott Helt Award from the Institute of Electrical and Electronic Engineers.
Rabinowitz has authored well over 100 patents and publications respectively, including papers in the top reproductive, transplant, and oncology journals. He led the development of the highest volume clinical genetic test in US history, which transformed pregnancy management, and oversaw the development of a technology that tracks tumor mutations in blood that has reshaped cancer management and received multiple FDA breakthrough designations. He also led the first whole genome polygenic modelling of embryos to prevent conferring disease risks to our children, as well as other breakthrough products. In 2024, Rabinowitz was named R&D Leader of the Year by R&D World.
Rabinowitz studied electrical engineering and physics at Stanford University. He received the Levin and Terman awards, the top academic awards offered by each department, and a graduate fellowship to the school of engineering, where he completed his doctorate in electrical engineering.